Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.1-4
"A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance. These five-year bimekizumab-bkzx results provide valuable evidence for clinical decision-making," said Andrew Blauvelt, MD, MBA, Chair, Medical Board, National Psoriasis Foundation. "The sustained complete skin clearance offers important insights into the potential of bimekizumab-bkzx's dual inhibition to provide long-term management of this chronic inflammatory condition."
Among patients with PSO only at baseline, who were at risk of progression to psoriatic arthritis (PsA), 68.7–71.6% achieved complete skin clearance (Psoriasis Area and Severity Index [PASI]100) at three years, generally consistent with the overall treated group, who achieved 72%.4 Similar results were seen in all patients with PSO, including those with PsA at baseline. Among the 153 US/Canadian patients who completed an open-label extension period to five years,* 67.7% achieved PASI100, while 84.9% achieved PASI90.1 In this subgroup over the five-year period, BIMZELX was generally well tolerated with no unexpected safety findings.1
"Psoriasis is a chronic condition that increases the risk of developing other serious health issues," said Fiona du Monceau, Executive Vice President, Head of Patient Evidence, UCB. "These five-year results highlight the robust potential of bimekizumab-bkzx in transforming patient outcomes by offering the possibility of lasting, complete skin clearance. Bimekizumab-bkzx is aiming to set a new standard for treatment success, and our belief in its innovative dual inhibition approach is reflected in our dedication to head-to-head trials, including the BE BOLD Phase 3 trial in psoriatic arthritis."
UCB's data for BIMZELX in moderate-to-severe PSO will be presented as six posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, U.S., March 7–11.1-6 These abstracts complement other BIMZELX data presented at AAD in hidradenitis suppurativa,7-13 psoriatic arthritis,14-16 ankylosing spondylitis, and non-radiographic axial spondyloarthritis,17-18 emphasizing UCB's leadership in addressing unmet health needs for people living with immune-mediated inflammatory diseases.
*All patients received BIMZELX every four weeks (Q4W) to Week 16, then received either Q4W or Q8W depending upon response to treatment. Receiving Q4W to Week 16, then Q8W thereafter is the approved dosing regimen (Q4W/Q8W). Results included patients receiving both Q4W/Q8W and Q4W/Q4W.
About Plaque Psoriasis:
Psoriasis is a common, chronic inflammatory disease with primary involvement of the skin.19 This skin condition affects men and women of all ages and ethnicities.20 Psoriasis signs and symptoms can vary, but may include red patches of skin covered with silvery-white scales; dry, cracked skin that may bleed; and thickened, pitted, or ridged nails.21 Psoriasis affects nearly three percent of the total population, or about 125 million people worldwide.
About Psoriatic Arthritis:
Psoriatic arthritis is a serious, highly heterogeneous, chronic, systemic inflammatory condition affecting both the joints and skin with a prevalence of 0.02 percent to 0.25 percent of the population.23 Psoriatic arthritis affects approximately 30 percent of people living with psoriasis.24 It manifests as joint pain and stiffness, skin plaques, swollen toes and fingers (dactylitis), and inflammation of the sites where tendons or ligaments insert into the bone (enthesitis).25 The burden on those living with PsA extends beyond physical discomfort to reduced quality of life, with comorbidities including hypertension, cardiovascular disease, anxiety, and depression.
About BIMZELX® (bimekizumab-bkzx):
BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.27 IL-17A and IL-17F are key contributors of chronic inflammation and damage across multiple tissues, with IL-17F increasing over time.27-30 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).
